Trilaciclib

From WikiMD.org
Jump to navigation Jump to search

Trilaciclib

Trilaciclib (pronounced tri-la-ci-clib) is a small molecule inhibitor of Cyclin-dependent kinases (CDK) 4 and 6. It is developed by G1 Therapeutics and is used in the treatment of various types of cancer.

Etymology

The name "Trilaciclib" is derived from the combination of the words "tri" (meaning three, referring to the three cyclin-dependent kinases it inhibits), "laci" (an abbreviation of "lactose", a sugar molecule that is part of the drug's structure), and "clib" (an abbreviation of "cyclin-dependent kinase inhibitor").

Usage

Trilaciclib is used in the treatment of small cell lung cancer (SCLC), breast cancer, and colorectal cancer. It is administered intravenously before chemotherapy to protect the immune system from damage caused by chemotherapy drugs.

Mechanism of Action

Trilaciclib works by inhibiting the activity of cyclin-dependent kinases 4 and 6. These kinases are proteins that control cell division. By inhibiting these kinases, Trilaciclib prevents cancer cells from dividing and growing.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski